Deutsche Bank AG lessened its stake in shares of USANA Health Sciences, Inc. (NYSE:USNA) by 62.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 93,286 shares of the company’s stock after selling 152,716 shares during the period. Deutsche Bank AG owned about 0.40% of USANA Health Sciences worth $10,981,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Janus Henderson Group PLC acquired a new position in shares of USANA Health Sciences in the 3rd quarter valued at about $258,000. BlackRock Inc. grew its stake in shares of USANA Health Sciences by 11.8% in the 3rd quarter. BlackRock Inc. now owns 1,076,327 shares of the company’s stock valued at $129,750,000 after buying an additional 113,961 shares in the last quarter. Credit Suisse AG grew its stake in shares of USANA Health Sciences by 110.4% in the 3rd quarter. Credit Suisse AG now owns 34,346 shares of the company’s stock valued at $4,141,000 after buying an additional 18,018 shares in the last quarter. JPMorgan Chase & Co. grew its stake in shares of USANA Health Sciences by 20.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 52,819 shares of the company’s stock valued at $6,367,000 after buying an additional 9,062 shares in the last quarter. Finally, Jefferies Group LLC bought a new stake in shares of USANA Health Sciences in the 3rd quarter valued at approximately $334,000. Hedge funds and other institutional investors own 53.37% of the company’s stock.
Separately, Tigress Financial initiated coverage on USANA Health Sciences in a research note on Tuesday. They issued a “buy” rating for the company. One research analyst has rated the stock with a hold rating and three have given a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $135.00.
USANA Health Sciences (NYSE:USNA) last announced its quarterly earnings results on Tuesday, February 5th. The company reported $1.32 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.33 by ($0.01). The firm had revenue of $299.02 million during the quarter, compared to the consensus estimate of $305.79 million. USANA Health Sciences had a net margin of 10.61% and a return on equity of 30.49%. The company’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.11 EPS. On average, research analysts expect that USANA Health Sciences, Inc. will post 5.18 earnings per share for the current year.
In other USANA Health Sciences news, Director Myron W. Wentz sold 20,645 shares of the company’s stock in a transaction that occurred on Friday, February 1st. The stock was sold at an average price of $115.36, for a total transaction of $2,381,607.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Gilbert A. Fuller sold 282 shares of the company’s stock in a transaction that occurred on Monday, February 11th. The stock was sold at an average price of $110.20, for a total value of $31,076.40. The disclosure for this sale can be found here. Insiders have sold 60,564 shares of company stock valued at $6,990,279 in the last ninety days. Company insiders own 42.50% of the company’s stock.
USANA Health Sciences Company Profile
USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include low-glycemic meal replacement shakes, snack bars, and other related products, which provide macro-nutrition.
Read More: What is the Ex-Dividend Date in Investing?
Want to see what other hedge funds are holding USNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for USANA Health Sciences, Inc. (NYSE:USNA).
Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.